DxCover

DxCover is a clinical-stage liquid biopsy company that has developed the PANAROMIC™ platform for early detection of multiple cancers. The company's technology, known as Multi-Omic Spectral Analysis (MOSA-Dx), analyzes the biochemical profile of a patient's blood serum using infrared spectroscopy and artificial intelligence to identify the presence or absence of disease.

DxCover's platform is designed to provide rapid, cost-effective, and non-invasive cancer diagnostics. The company is currently conducting clinical trials for the detection of brain, colorectal, and lung cancers. By detecting cancers at an earlier stage, DxCover aims to improve patient outcomes and reduce healthcare costs. The company's business model is focused on the development and commercialization of its diagnostic tests for use in clinical settings, such as hospitals and laboratories.

Keywords: liquid biopsy, cancer diagnostics, early detection, artificial intelligence, spectroscopy, multi-omic, PANAROMIC, MOSA-Dx, clinical trials, non-invasive